Shared decision making underpins good health care

17 June 2021 - Shared decision making between service users and health care professionals is an integral part of health care, ...

Read more →

Ontozry scores MHRA authorisation for focal-onset seizures

17 June 2021 - The MHRA has granted Arvelle Therapeutics’ Ontozry a marketing authorisation for the adjunctive treatment of focal-onset ...

Read more →

How the patient voice is becoming vital for drug approval

14 June 2021 - Rebecca Sanders from Lipodystrophy UK tells us how the patient voice helped convince NICE to approve a ...

Read more →

GBT’s voxelotor is first sickle cell disease treatment to receive promising innovative medicine designation in the UK

14 June 2021 - Global Blood Therapeutics announced today that the MHRA in the United Kingdom has granted a Promising Innovative ...

Read more →

Opdivo plus Yervoy scores NICE backing for certain bowel cancer patients

14 June 2021 - Bristol Myers Squibb’s immunotherapy combination Opdivo plus Yervoy has been recommended by NICE for the treatment ...

Read more →

NICE to reassess Kyowa Kirin’s Poteligeo

14 June 2021 - NICE will reassess Kyowa Kirin’s rare blood cancer treatment Poteligeo after upholding an appeal launched by ...

Read more →

Astellas’ Xtandi bags NICE approval in prostate cancer

10 June 2021 - Astellas’ oral treatment Xtandi has received approval from NICE for the treatment of metastatic hormone-sensitive prostate ...

Read more →

NICE recommends several treatment options to help thousands with moderate rheumatoid arthritis

10 June 2021 - Around 25,000 people with moderate rheumatoid arthritis that has not responded to conventional therapies are set to ...

Read more →

Integrating early economic evaluation into target product profile development for medical tests: advantages and potential applications

7 June 2021 - Target product profiles outline the characteristics that new health care technologies require to address an unmet clinical ...

Read more →

Amicus Therapeutics announces United Kingdom’s MHRA grants early access to AT-GAA

8 June 2021 - Permits All Eligible Individuals with Late-Onset Pompe Disease Access to AT-GAA Prior to Marketing Authorization in the ...

Read more →

NICE recommends Tecentriq for first-line NSCLC

7 June 2021 - NICE has recommended Roche’s Tecentriq (atezolizumab) monotherapy for untreated metastatic non-small cell lung cancer. ...

Read more →

New Skyrizi (risankizumab) 150 mg presentation pre-filled pen and pre-filled syringe Approved by the MHRA

4 June 2021 - Approval based on results showing the new formulation of risankizumab 150 mg demonstrated bioequivalence to two injections ...

Read more →

MHRA authorises Pfizer/BioNTech’s COVID-19 vaccine for 12 to 15 year-olds

7 June 2021 - The UK MHRA has extended the authorisation of Pfizer/BioNTech’s COVID-19 vaccine for use in children aged ...

Read more →

GSK’s PD-1 inhibitor Jemperli approved in the UK

7 June 2021 - GSK's PD-1 inhibitor Jemperli has been authorised by the UK MHRA for the treatment of recurrent ...

Read more →

NICE publishes appraisal consultation document for medicine for excessive daytime sleepiness

3 June 2021 - The Department of Health and Social Care has asked the NICE to produce guidance on using pitolisant ...

Read more →